Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Leukemia » Leukemia, Myeloid
Description
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. MeSH
Hierarchy View
Subtype Terms (7)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
245 drugs (127 approved, 118 experimental)
Leukemia, Myeloid, Acute
869 drugs (244 approved, 625 experimental)
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
128 drugs (99 approved, 29 experimental)
Leukemia, Myelomonocytic, Acute
69 drugs (46 approved, 23 experimental)
Leukemia, Myelomonocytic, Chronic
199 drugs (113 approved, 86 experimental)
Leukemia, Myelomonocytic, Juvenile
55 drugs (37 approved, 18 experimental)
Sarcoma, Myeloid
35 drugs (28 approved, 7 experimental)
Phase 3 Indicated Drugs (20)
Phase 2 Indicated Drugs (27)
Organization Involved with Phase 4 Indications (49)
Organization Involved with Phase 3 Indications (202)
Accutest Research Laboratories (I) Pvt. Ltd.
Albert Einstein Israelite Hospital
All India Institute of Medical Sciences
Badalona Hospital Germans Trias i Pujol
Blood and Marrow Transplant Clinical Trials Network
Cancer and Leukemia Group B (CALGB)
Center for International Blood and Marrow Transplant Research
Central European Leukemia Study Group
Changzhou No.2 People's Hospital
Chinese Academy of Medical Sciences
CHU Haut-Leveque Pessac 33604 France
Cohen Children's Medical Center of New York
Cyclacel Pharmaceuticals, Inc.
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)
Eastern Cooperative Oncology Group
European Organisation for Research and Treatment of Cancer
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
French Innovative Leukemia Organisation
German Federal Ministry of Education and Research
Gottfried Wilhelm Leibniz Universität Hannover
Gruppo Italiano Trapianto di Midollo Osseo
HOVON - Dutch Haemato-Oncology Association
Huai'an Second People's Hospital
National Cancer Institute, France
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
People's Liberation Army of China
Physicians, Innovations, Science for Children Fund
Royal Liverpool & Broadgreen University Hospitals NHS Truts
Shandong Province Qianfoshan Hospital
Shanghai Ruijin Hospital North
Shengli Oilfield Central Hospital
Organization Involved with Phase 2 Indications (358)
Associazione Italiana per la Ricerca sul Cancro
Australasian Leukaemia and Lymphoma Group
Azienda Ospedaliera Universitaria Senese
Bio-Cancer Treatment International Limited
BioMed Valley Discoveries, Inc
Case Western Reserve University
Chao Family Comprehensive Cancer Center
Children's National Medical Center
Chongqing Precision Biotech Co., Ltd
City of Hope National Medical Center
Clinica Universidad de Navarra
Colorado Blood Cancer Institute
Department of Health and Human Services
Department of Health, United Kingdom
Doris Duke Charitable Foundation
ECOG-ACRIN Cancer Research Group
Epidemiological and Clinical Research Information Network
Federal University of Health Science of Porto Alegre
Federal University of Rio Grande do Sul
Froedtert Memorial Lutheran Hospital
Fundacion CRIS de Investigación para Vencer el Cáncer
Fundación Teófilo Hernando, Spain
Groupe Francophone des Myelodysplasies
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Hannover Clinical Trial Center GmbH
Herbert Irving Comprehensive Cancer Center
Hôpital Mignot, Versailles Paris
Hopital Rene Huguenin_Intitut Curie_Paris
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Hospital San Pedro de Alcantara
Hospital Santa Marcelina, Sao Paulo, Brasil
Hospital Universitario Ramon y Cajal
Huazhong University of Science and Technology
Innovative Therapies For Children with Cancer Consortium
Innovent Biologics (Suzhou) Co. Ltd.
Istituto Nazionale per lo Studio e la Cura dei Tumori
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Katholieke Universiteit Leuven
Korea Research Institute of Bioscience and Biotechnology
Memorial Sloan-Kettering Cancer Center
Methodist Cancer Center, Houston, Texas
Moorgreen Hospital, Southampton
National Hospital Organization, Mito Medical Center
National Institutes of Health (NIH)
New Mexico Cancer Care Alliance
North Shore Hospital, New Zealand
Norwegian University of Science and Technology
Oregon Health and Science University
Pavlov First Saint Petersburg State Medical University
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Philipps University of Marburg
Rocky Mountain Cancer Centers - Denver Midtown
Royal Marsden Hospital NHS Trust
Shanghai institute of Hematology
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Shenzhen Geno-Immune Medical Institute
Shijiazhuang Pharma Group (CSPC)
Shimousa Hematology Study Group
Suzhou Yasheng Pharmaceutical Co., Ltd
The First People's Hospital of Yunan Province
The Foundation Institute San Raffaele G. Giglio of Cefalù
The Korean Society of Blood and Marrow Transplantation
The Korean Society of Hematology
The Korean Society of Pediatric Hematology Oncology
The University of Texas, Dallas
Tokyo Metropolitan Komagome Hospital
Universidad Autonoma de Madrid
Universita' Cattolica del Sacro Cuore
Université catholique de Louvain
University Hospital of Mont-Godinne
University Hospital of North Norway
University of Alabama, Birmingham
University of California, Davis
University of California, San Diego
University of California, San Francisco
University of Colorado, Denver
University of Erlangen-Nuremberg
University of Medicine and Dentistry of New Jersey
University of North Carolina at Chapel Hill
University of Roma La Sapienza
University of Southern California
University of Southern Denmark
Virginia Commonwealth University
Vita-Salute University of Milano. Italy
Organization Involved with Phase 1 Indications (125)
Alex's Lemonade Stand Foundation
American Society for Blood and Marrow Transplantation
Applied Physiology Research Center
Arbeitsgemeinschaft medikamentoese Tumortherapie
Big Ten Cancer Research Consortium
China Academy of Chinese Medical Sciences
Damon Runyon Cancer Research Foundation
GCP-Service International Ltd. & Co. KG
Georgia Institute of Technology
Hamilton Health Sciences Corporation
Hebei Senlang Biotechnology Inc., Ltd.
High Impact Clinical Research Support Program
Innovative Clinical Research, Inc.
Pharmaceutical Research Associates, Inc. (PRA)
Seyyed-alshohada hospital of Isfahan
Sunshine Lake Pharma Co., Ltd.
Technical University of Denmark
Translational Drug Development
University of British Columbia
University of Illinois at Chicago
University of Maryland, College Park
University of Science and Technology of China
William Lawrence and Blanche Hughes Foundation
Organization Involved with Other Experimental Indications (17)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
